Not for publication or presentation
|
|
- Emory Potter
- 8 years ago
- Views:
Transcription
1 MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: ; Fax: ; Mary Evelyn D. Flowers, MD, Fred Hutchinson Cancer Research Center Telephone: ; Fax: ; Alvaro Urbano-Ispizua, MD, Universitario Virgen del Rocio Telephone: ; FAX: ; Peigang Li, MS, CIBMTR Statistical Center Milwaukee Telephone: ; Fax: ; Tao Wang PhD, CIBMTR Medical College of Wisconsin Telephone: ; Fax: ; Mukta Arora MD, MS, CIBMTR Minneapolis Telephone: ; Fax: ; Stephen Spellman, MS, National Marrow Donor Program Telephone: ; Fax: ; 1. Introduction Dr. Pavletic opens the meeting at 2:45 PM. He introduced the GVHD team, including co-chair, scientific directors, and statisticians. Unfortunately, co-chair Dr. Alvaro Urbano-Ispizua is unable to join us today. Joining us today is a new co-chair, Dr. Corey Cutler, MD; Dana Farber Cancer Institute, Telephone: ; FAX: , corey_cutler@dfci.harvard.edu. Drs. Pavletic, Flowers and Cutler, chaired the meeting. The voting guidelines were presented. Dr. Mukta Arora asked Dr. Flowers to present a gift to Dr. Pavletic, the retiring co-chair, in acknowledgement of his leadership and hardwork he provided all these past years. Dr. Flowers recognized Dr. Pavletic efforts towards studies focused on chronic GVHD and welcomed Dr. Cutler as a great asset to have in the GVHD Working Committee as the new co-chair elected this year. Dr. Flowers asked each team member of the CIBMTR GVHD Working committee to do a selfintroduction, including the new co-chair, and the new statistician, Peigang Li. Dr. Flowers asked for approval of the 2009 Tandem minutes. The motion was passed and the minutes were approved. 2. Accrual summary Due to time limit, the accrual summary was not presented. It was indicated that this information is posted on the web site. 3. Published or submitted papers Dr. Arora indicated the papers that have been published as follows:
2 a. D96-01 Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, MacMillan ML, Sanders J, Wall D, Kernan NA. Recent Decrease in Acute GVHD in Children with Leukemia Receiving Unrelated Donor Bone Marrow Tranplants. Biol Blood Marrow Transplant 15: , b. D01-91 Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 145: , Studies in Progress - Below are the studies that were presented: a. GV05-02: Risk factors and outcome of agvhd after MUD (N Chao/ M Jagasia) Dr. Jagasia presented the study on behalf of the other PIs. The study is intended to identify prognostic factors for incidence of agvhd after allo-transplant and evaluate interactions of agvhd with other factors and outcomes such as age, OS, LFS, TRM, and REL. He focused on multivariate analysis of agvhd and OS. He showed background of the data: TX year 1995 to 2005, T-cell replete only, BM/PB, HLA-id/MUD (8/8 match), including disease AML, ALL, CLL and MDS It was decided to perform the analysis based on age group (pediatric/adults) and donor status (related/unrelated). The data includes many RIC patients (n=488). The agvhd models are for peds and adults, trying to predict Grade II-IV agvhd after transplant. The prognostic factors include FK506, GVHD prophylaxis (protective effect against agvhd), combinations of conditioning regimens (tbi vs no tbi), and sources of stem cells. Pediatric patients have a protective effect for MAC, no tbi and BM transplants. For adults, disease status, sex mismatch, GVHD prophylaxis are important predictive factors as well. A number of other factors also have protective effects. Age and some factors play important roles in OS for the four groups: peds/related, peds/unrelated, adults/related, adults/unrelated. The best overall protection comes from MAC, no tbi and BM transplants for related donors. For unrelated donors, the final predictors include recipient age, disease status at TX, CMV match, and HLA mismatch. b. GV04-02/GV05-03: Relapse in patients with cgvhd (M Boyiadzis/ DA Jacobsohn) This study merged from two studies. Part A of the Study was presented by Dr. Jacobsohn 1) The goal of this study was to identify risk factors and stratify high risk group of patients. The data has over 5000 patients with at least 5 year follow-up. The strength of the data is that it has over one third of pediatric patients (peds). The univariate analysis includes NRM, REL, DFS and OS. The OS at 5 years is 55% for patients of any age, and adults/peds has similar risk factors. Patients were divided into six risk groups based on the scores calculated from several factors, including age, acute GVHD status, donor, disease status, kps, etc. The risk strata clearly showed the separation of these risk groups. At the request of the GVHD committee, Dr. Jose Perez-Simon presented another chronic GVHD study from the EBMT (adults/peds) in hopes to identify other potential cohorts that could be used in a validation study for the risk stratification model results of the GV04/GV05-03 studies. The EBMT study included patients with chronic GVHD who survived without relapse at least 100 days after transplant. The OS at 5 years was 52%. Most patients with cgvhd of overlap type had progressive type of onset. Dr. Perez-Simon showed the results of the multivariate analysis of prognostic factors based on the NIH scoring system of cgvhd classification (mild, moderate, severe), and the type of GVHD onset (progressive, de novo, quiescent). Four subgroups of patients with different survival rates were identified. Both the NIH scoring system and the type of cgvhd onset had predictive values for outcomes after PBSCT.
3 There were questions about the adequacy of this cohort to serve as a validation cohort, due to difference in the patient selection ( the CIBMTR study included patients who did not survive 100). There were also inquiries about the availability and accuracy of KPS data at the time of diagnosis of cgvhd in both the US and EBMT cohorts. 2) Dr. Pavletic presented Part B of the study. It was shown that cgvhd is associated with fewer relapses after transplant. The goal is to identify cgvhd related features in the registry to differentiate relapse risk groups in a large cohort of patients. The analysis is on hold. The reason is different requirements of the data. Patients who did not relapse at 1 year will be subject to subsequent analysis where the data is still being checked and completed. This study is important in its ability to study the risk factor for late relapse of malignancies (i.e., > 1yr after transplant) among patients diagnosed with cgvhd at any time within 1 year and remained alive at 1 year. c. GV06-01: MTX vs non-mtx GVHD prophylaxis (C Cutler) The study has not gone very far for some good reasons. Without clean observations the study was unable to do the comparison between related and unrelated donors. Table 2 in the attachment shows the four groups of donor type and MTX. Marcelo Pasquini, co-pi of this study, volunteered to move forward and proceed with cleaner and simpler analysis to answer straightforward questions in RIC/NST comparing commonly used regimens in GVHD preventions. There are about 900 patients to be analyzed. d. GV06-04: Current trends in cgvhd (S Arai) Dr. Arai reviewed the trends study of 10-year period, , with 3 years follow-up. Patients must survive 100 days after first TX. Primary goal is to observe GVHD incident trends of last 10 years. Secondary objective is to look at severity trend using surrogate markers such as type of onset, organ involvement, disease status at DX, cgvhd-specific mortality, and overall mortality. Univariate and multivariate analyses determine the associations of clinical practices in terms of graft source, donor type, conditioning regimen, and how they affect incidence trend of cgvhd. Tables in the attachment show the trends with and without cgvhd over the 10 year period, as well as patient demographics broken down by year groups, , and Questions about the relevance of this study were raised. This study was argued to be a high priority because it will describe the incidence and severity trends of cgvhd in the context of clinical practice, especially with this large set of data involving multiple institutions. It will be a descriptive study. The primary objectives are (1) incidence of cgvhd; (2) time trends in cgvhd development. e. GV08-01: DRB1 ag and DR15 in GVHD/GVL in HLA matched Sibling transplant (M Battiwalla) The study s protocol has been finalized. DR15 has been shown to have effects on sensitivity to immunosuppressant therapy, GVHD, reduction in agvhd and relapse incidence, and could be a marker for greater susceptibility. The results have been evaluated in HLA-id sibs to show improved PFS and OS. The data includes patients with first TX. Exclusions are HLA mismatch (molecular typing), T-cell depletion, and synergeic donors. The study focuses on the main effect of presence of DR15 vs absence of DR15, and subsequently homogeneous vs. heterogeneous states, and *1501 vs *1502 groups. Common outcomes include GVHD, PFS and OS. In comparison, there is an abstract presentation in ASH 2009 involving DR15 but its multivariate analysis did not show differences in main outcomes. Thus, the current study is looking to answer the question that DR15 has major effect on the outcomes of graft vs. leukemia responses. f. GV08-02: agvhd vs GVT potential for graft engineering by T-cell dose (A Saad/ M Sharma)
4 The study is looking for an optimal T cell dose that can balance the survival of allo TX and GVHD. The hypothesis is to test whether high grade agvhd and the GvT are separable, and if there exists a cell dose range of both CD4+ and CD8+ T-cell which promote GvT. From a small retrospective study, the statistical model was used to identify a dose range for CD4+/CD8+ where patients with lower cell dose had a significant risk for Grade II-IV agvhd while the survival curve did not show difference for higher or lower doses. This would indicate that we can reach the same survival by giving patients lower cell dose without risk of getting agvhd. The CIBMTR registry data shows 17% patients with Grade III-IV agvhd. The study looks at both BM and PBSC transplants. g. GV08-03: Risk factors for agvhd after matched Sib HCT (RIC) for Leukemia (O Ringdén) It is to compare RIC with MAC patients as well as evaluate risk factors for Grades II-IV agvhd. Patients population are , HLA-id sibs and 8/8 matched donors, PB or BM, first transplant only, and T-cell depletion will be excluded. Outcomes include cumulative incidence of agvhd and risk factors for grades II-IV and III-VI acute GVHD between RIC and MAC. Univariate analysis shows that there is a difference for Grade II-IV between RIC and MAC but no difference for Grade III-IV. This study has a fair amount of overlap with GV05-02 so it would be better to restrict to risk factors only and additionally capture the onset of GVHD. h. GV08-04: Relapse outcome w/wo cgvhd (M Boyiadzis) The study looks into whether there is any difference between patients without cgvhd after allo TX and those with cgvhd, describes outcomes and prognostic variables for patients who relapse, and characteristics of patients who progressed. There are over 2100 patients who meet the selection criteria in the CIBMTR registry. i. GV08-05: cgvhd in RIC (S Pavletic) It is in the protocol development stage and a lot of good comments along the way have been considered. It looks into the prognostic factors for development of cgvhd and outcomes after RIC transplant. Currently the study only includes PBSCT and questions were raised to include BM. The idea is that the biological modifying factors in association with prognostic factors have not been well addressed. This study was compared and contrasted to Dr. Arai s trends in chronic GVHD study (GV06-04) which is looking at all patients including RIC and the onset of GVHD. j. GV08-06: GVL after 8/8 URD vs HLA matched sib RIC or NST (O Ringdén) It compares GvL effect for RIC or NST patients from unrelated or HLA-id sibs donors. Eligible patients are transplants and outcomes include relapse, TRM and DFS, and different grades of agvhd/cgvhd. Dr. Ringdén presented the latest table of available cases for analysis. The ages for donor and recipient are important factors. 5. Deferred Studies a. GV05-05 DLI after NST/focus on GVHD (DR Couriel/ RM Saliba) Dropped. b. GV07-01 Stem cell dose in unrelated BMT (HJ Khoury) Dropped (or Merge with a study in GSWC) 6. Future/ Proposed studies a. PROP Conditioning/Graft Source in G-CSF induced GVHD
5 (O Ringdén) There is a clinical controversy whether G-CSF increases GVHD or not. A European study suggests that G-CSF increases GVHD as well as survival but CIBMTR studies did not show such an effect. A recent mouse model study on Nature prompted the current proposal hypothesized that G-CSF induces GVHD in patients with TBI or BM graft. G-CSF given before day 14 induces GVHD. Standard outcomes are analyzed. The characteristics table was presented. There are about 8000 patients and almost 1/3 of them were treated with G-CSF. A question suggested excluding patients with graft failures. 7. Other Business The meeting adjourned at 4:36PM. Dr. Jose Perez-Simon will be added to the GVHDWC contact list. pesimo@usal.es The GVWC meeting agreed to drop the following two studies: Study # and PI Status at tandem 02/10 Anticipated status by 06//10 GV05-05 (DR Couriel/ RM Saliba) Deferred Dropped GV07-01 (HJ Khoury) Deferred Dropped The voting score result is as follows: Study/Proposal Status subtotal votes average score PROP GV06 01 Prot dev GV06 04 Prot dev GV08 02 Prot dev GV08 04 Prot dev GV08 06 Prot dev Note: Votes and scores are not related to priority for GV Top priorities are usually given to those already in advanced status.
Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationNavelstrengbloed tegen kanker
Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationSESUG 2011 INTRODUCTION. Paper GH-12
Paper GH-12 Development of a SAS Macro for Automated Data Cleaning of Major Outcomes of Interest in Hematopoietic Cell Transplantation Peigang Li, Min Chen and Zhiwei Wang, CIBMTR, Milwaukee, WI ABSTRACT
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014 The ideal HSCs source Immediate availability Few HLA restrictions
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationHematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD
Hematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD Stem cell transplantation Autologous Autologous stem cell collection Freeze Stem Cells
More informationGraft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
More informationOutcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)
Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationMyeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants
Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationHematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes
Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia
More informationUmbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation
Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Mary J. Laughlin, MD Associate Professor of Medicine and Pathology Dr. Donald and Ruth Weber Goodman Professor of Innovative
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationStammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del
Allogene Neues vom immunologischen Ctrl-Alt-Del Prof. Dr. med. Wolfgang Bethge Allogene am ASH Insgesamt 715 Abstracts zum Thema Auswahl: Azacitidine als Überbrückung zu allogenen SZT bei MDS Ergebnis
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationOUR JOURNEY THROUGH THE YEARS
The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist
More informationCenter Outcomes Reporting in the US 2015. Successes and Challenges J. Douglas Rizzo, MD MS
Center Outcomes Reporting in the US 2015 Successes and Challenges J. Douglas Rizzo, MD MS Overview of the Stem Cell Therapeutic Research Acts* US Department of Health and Human Services Advisory Council
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationHow to select a donor and product for allogeneic HCT
How to select a donor and product for allogeneic HCT Dr Bronwen Shaw 10 February 2015 Overview Who (and where) are the donors What factors determine how we choose between them Acquisition Clinical Donor
More informationTelephone: 414 805 0700; Fax: 414 805 0714; E mail: meapen@mcw.edu
Not for publication or presentation A G E N D A CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Grapevine, TX Thursday, February 27, 2014, 2:45 4:45 pm Co Chair: Co Chair: Co Chair: Statisticians:
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationAdvances in HSC Transplantation for Myelodysplasia: Cord Blood Transplantation & RIC
Advances in HSC Transplantation for Myelodysplasia: Cord Blood Transplantation & RIC -7-6 -5-4 -3-2 -1 0 30 100 CSA/ MMF Juliet N. Barker, MBBS (Hons), FRACP Associate Attending Director Cord Blood Transplant
More informationThe Value of Cord Blood Stem Cells. Mona Shafey, MD, FRCPC Medical Grand Rounds October 25 th, 2011
The Value of Cord Blood Stem Cells Mona Shafey, MD, FRCPC Medical Grand Rounds October 25 th, 2011 Objectives To discuss umbilical cord blood as a stem cell source and the role of umbilical cord blood
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationCord Blood Transplant Past and Future. E. Gluckman Eurocord ISCT Paris 24/04/2014
Cord Blood Transplant Past and Future E. Gluckman Eurocord ISCT Paris 24/04/2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationWBMT Global Survey. Helen Baldomero Cape Town November 2014. Worldwide Network for Blood and Marrow Transplantation
WBMT Global Survey Helen Baldomero Cape Town November 214 NGO in official relations with World Health Organization Leukemias LPD Solid tumors Non - Malignant disorders NGO in official relations with World
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationThe future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca
The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings Prof. Tony Pagliuca UK STEM CELL STRATEGIC FORUM The future of unrelated donor SCT in the UK Antonio Pagliuca, Transplant
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationSTEM CELL THERAPEUTIC OUTCOMES DATABASE
C W Bill Young Cell Transplantation Program STEM CELL THERAPEUTIC OUTCOMES DATABASE BUS06_1ppt Stem Cell Therapeutic and Research Act of 2005 (PL 109-129) 129) Authorizing law, preceded by efforts to:
More informationImmunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
More informationHAPLO-CORD HEMATOPOIETIC STEM CELL TRANSPLANTATION
HAPLO-CORD HEMATOPOIETIC STEM CELL TRANSPLANTATION Frequency, Risk Factors and Outcomes of Cord Graft Failure (CGF) After Haplo-Cord Transplantation Stephanie B. Tsai, MD Fellow in Hematology-Oncology
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationCord Blood Bank Business Plan
Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationUmbilical Cord Blood Stem Cells Current Status & Future Potential
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu
More informationBackground: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?
University of Michigan Best Practices Pam James, MS CCRP Administrative Manager, Data Management Bone Marrow Transplant, Hematologic Malignancies & NCCN Background: The data management team at the University
More informationDonor and stem cell source selection. 21 November 2013 E. Baudoux
Donor and stem cell source selection 21 November 2013 E. Baudoux Table of contents Introduction HPC sources and donor types HLA and matching Unrelated donor searches Donor choice and eligibility Search
More informationStem Cell Transplantation in Severe Aplastic Anemia
Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia
More informationProgram Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
More informationHaematopoietic stem cell transplantation in Hong Kong
S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was
More informationTrasplante de Células Madre Hemopoyéticas. Dos décadas de progreso
Trasplante de Células Madre Hemopoyéticas. Dos décadas de progreso A. Urbano Ispizua Hospital Clinic, Universidad de Barcelona Noviembre de 2011 Al comienzo, estaba la médula ósea Al comienzo, estaba la
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More information* CHAPTER 6. Choice of the donor according to HLA typing and stem cell source. Eliane Gluckman
* CHAPTER 6 Choice of the donor according to HLA typing and stem cell source Eliane Gluckman CHAPTER 6 Choice of the donor according to HLA typing and stem cell source 1. Introduction Allogeneic haematopoietic
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationUpdate on Cord Blood Transplants
Update on Cord Blood Transplants Vanderson Rocha, MD, PhD Scientific Director of Eurocord Chair of Cord Blood Subcommittee of EBMT Agence de Biomedecine and Saint Louis Hospital, Paris, France Hematopoietic
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationConnection. CIBMTR Clinical Research Associates Mentoring Committee
Newsletter: Data Connection CIBMTR Clinical Research Associates Mentoring Committee Friday, September 12, 2008 Mark your calendars for the 2009 BMT Tandem Meeting. It will be held at the Tampa Convention
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationBlood and Marrow Stem Cell Transplantation
Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationHematopoietic Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation Koh Liang Piu Adult Stem Cell Transplant Program Department of Hematology Oncology National University Hospital 27 Feb 2009 Year 2007 52 SCT in 45 patients Type
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationData Reporting Problems
Data Reporting Problems Shelley Hewerdine & Khrystyna Valkiv Istanbul, 23rd March 2015 #EBMT2015 www.ebmt.org Format of this session Recent EBMT Registry work Improving Data Quality Data reporting Quiz
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationCord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD
Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer
More informationProgress Report JANUARY DECEMBER. Sharing Knowledge. Sharing Hope.
Progress Report JANUARY DECEMBER 2014 Sharing Knowledge. Sharing Hope. CIBMTR (Center for International Blood and Marrow Transplant Research ) is a research collaboration between the National Marrow Donor
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationMaintenance Steroid Avoidance in Pediatric Heart Transplantation is Associated with Excellent Graft Survival
Maintenance Steroid Avoidance in Pediatric Heart Transplantation is Associated with Excellent Graft Survival Scott Auerbach, MD, Jane Gralla, PhD, Shelley Miyamoto, MD, David Campbell, MD, and Biagio Pietra,
More informationStem Cell Transplantation in Adults
Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationObjectives. Cord Blood. Case 1. Case 1. Case 1. Case 1. To provide a framework for answering a family s questions about cord blood storage.
Cord Blood Should we save the baby s cord blood? Meghan A. Higman, MD, PhD Clinical Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology Assistant Professor of Oncology Pediatrics
More informationHealth Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
More informationUnrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N.
Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N. Barker Adult Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering
More informationUMHS-PUHSC JOINT INSTITUTE
Imaging Biomarkers for Staging and Assessing Response to Therapy in Multiple Myeloma Qian Dong, MD. Radiology University of Michigan Wei Guo, MD. Orthopedic Oncology Peking University Second Hospital Team
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationHow To Treat Multiple Myeloma With A Stem Cell Transplant
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Nonmyeloablative Allogeneic
More informationNew Zealand Bone Marrow Donor Registry
Title: Authorised by: SECTION 9.0 NZBMDR STANDARDS PROCESS FOR AN UNRELATED STEM CELL DONOR WORKUP & IDENTIFICATION OF CORD BLOOD UNITS Executive Officer Contributing Authors: Sally Gordon Dr Hilary Blacklock
More informationDie Periphere Blutstammzell- Transplantation
Die Periphere Blutstammzell- Transplantation Martin Körbling DGHO, Stuttgart, Oktober 2012 Der Ursprung des Begriffs Stammzelle Alexander Maximow 1909 A. Maximow, Fol. Haematol. 8;1909:125-134 St. Petersburg
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationSEARCHING FOR A BONE MARROW DONOR
SEARCHING FOR A BONE MARROW DONOR Angela received a bone marrow transplant from an unrelated donor to treat her non-hodgkin s lymphoma. INFORMATION FOR PATIENTS AND THEIR FAMILIES For patients who need
More informationHow To Kill Gvhd
: in-vivo HSV-TK suicide machinery is effective in GvHD control and provide a long-term immune-suppressive treatment-free survival Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute.
More informationThe use of monoclonal antibodies in the setting of HSCT
The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin
More informationP R E S S K I T 2013 TABLE OF CONTENTS. About the European Group for Blood and Marrow Transplantation
TABLE OF CONTENTS About the European Group for Blood and Marrow Transplantation Haematopoietic Stem Cell Transplantation (HSCT): Key facts & figures EBMT Data - A foundation for cutting-edge research Clinical
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationRole of allogeneic stem cell transplantation in relapsed or refractory Hodgkin s disease
Symposium article Annals of Oncology 13 (Supplement 1): 128 132, 2002 DOI: 10.1093/annonc/mdf626 Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin s disease A. Sureda 1 & N.
More information5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More information